GIPR Agonist Long Acting therapeutic (Eli Lilly and Company)

N/A

Report date: 2025/12/08 17:14:01

Base Information

Drug NameGIPR Agonist Long Acting therapeutic (Eli Lilly and Company)
Drug Alias NameGIPR Agonist Long Acting (Eli Lilly and Company)
ClassificationBiologics
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A